Information Provided By: 
Fly News Breaks for October 30, 2015
OSIR
Oct 30, 2015 | 10:17 EDT
Piper Jaffray analyst Edward Tenthoff attributes the weakness in Osiris to an "overreaction and misinterpretation" of newly issued FDA draft guidance on homologous use of tissue and cellular products. Grafix will not be removed from the market and this guidance is exactly why the company has been planning Phase III trials and a BLA filing for Grafix, Tenthoff tells investors. The analyst recommends buying the stock amid the weakness and keeps his Overweight rating and $28 price target on shares.
News For OSIR From the Last 2 Days
There are no results for your query OSIR
